|Bid||4.26 x 0|
|Ask||4.40 x 0|
|Day's Range||4.26 - 4.40|
|52 Week Range||2.80 - 5.20|
|Beta (3Y Monthly)||0.33|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.25|
Company Announcement 14 September 2018. Pursuant to section 30 of Consolidated Act no. 12 of 8 January 2018 on capital markets, as amended, NeuroSearch A/S hereby announces to have received a major shareholder ...
Announcement 14 September 2018 At the company’ s Extraordinary General Meeting held today, the following resolution was passed: Morten Mathiesen and Mikkel Primdal Kæregaard were elected to the Board of ...
On 16 May 2018, NeuroSearch A/S ("NeuroSearch") entered into an agreement with, among others, Teva Pharmaceutical International GmbH ("Teva") (the "Agreement") to release Teva from all outstanding obligations pursuant to the agreement from 2012 concerning the transfer of NeuroSearch's rights in and to Pridopidine. NeuroSearch has been informed that Teva has completed a definitive agreement relating to the sale and transfer of Teva's right in and to Pridopidine with effect from 9 September 2018, and that NeuroSearch therefore pursuant to the Agreement will receive a cash payment of USD 450,000.
Below please find the H1 report 2018. The full report is available in the enclosed PDF file. NeuroSearch posted an operating loss of DKK 2.8 million in H1 2018. NeuroSearch posted a net loss of DKK 3.0 ...
Company announcement 23 August 2018 Pursuant to section 30 of Consolidated Act no. 12 of 8 January 2018 on capital markets, as amended, NeuroSearch A/S hereby announces to have received a major shareholder ...
With reference to NeuroSearch A/S`s ("NeuroSearch") announcement of 27 April 2018 (no. 6 - 18) concerning a conditional, voluntary takeover offer to the shareholders of NeuroSearch to acquire the entire share capital of NeuroSearch (excluding any treasury shares) against cash consideration of DKK 4.00 per share (the "Offer"), Gefion Group Investments A/S ("Gefion") has today published an offer document and an acceptance form (attached to the offer document) pursuant to section 4(2) of Danish Executive Order no. 1171/2017 on Takeover Bids.
In this analysis, my focus will be on developing a perspective on NeuroSearch A/S’s (CPSE:NEUR) latest ownership structure, a less discussed, but important factor. Ownership structure of a company hasRead More...